1. Home
  2. ANAB vs SEI Comparison

ANAB vs SEI Comparison

Compare ANAB & SEI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ANAB
  • SEI
  • Stock Information
  • Founded
  • ANAB 2005
  • SEI 2014
  • Country
  • ANAB United States
  • SEI United States
  • Employees
  • ANAB N/A
  • SEI N/A
  • Industry
  • ANAB Biotechnology: Pharmaceutical Preparations
  • SEI
  • Sector
  • ANAB Health Care
  • SEI
  • Exchange
  • ANAB Nasdaq
  • SEI NYSE
  • Market Cap
  • ANAB 759.5M
  • SEI 681.1M
  • IPO Year
  • ANAB 2017
  • SEI 2017
  • Fundamental
  • Price
  • ANAB $19.59
  • SEI $21.78
  • Analyst Decision
  • ANAB Buy
  • SEI Strong Buy
  • Analyst Count
  • ANAB 10
  • SEI 5
  • Target Price
  • ANAB $37.75
  • SEI $48.25
  • AVG Volume (30 Days)
  • ANAB 589.1K
  • SEI 1.5M
  • Earning Date
  • ANAB 05-05-2025
  • SEI 04-28-2025
  • Dividend Yield
  • ANAB N/A
  • SEI 2.22%
  • EPS Growth
  • ANAB N/A
  • SEI N/A
  • EPS
  • ANAB N/A
  • SEI 0.50
  • Revenue
  • ANAB $111,872,000.00
  • SEI $371,533,000.00
  • Revenue This Year
  • ANAB N/A
  • SEI $60.08
  • Revenue Next Year
  • ANAB $44.69
  • SEI $33.81
  • P/E Ratio
  • ANAB N/A
  • SEI $42.93
  • Revenue Growth
  • ANAB 387.20
  • SEI 33.59
  • 52 Week Low
  • ANAB $12.21
  • SEI $8.09
  • 52 Week High
  • ANAB $41.31
  • SEI $39.03
  • Technical
  • Relative Strength Index (RSI)
  • ANAB 48.98
  • SEI N/A
  • Support Level
  • ANAB $18.51
  • SEI N/A
  • Resistance Level
  • ANAB $21.52
  • SEI N/A
  • Average True Range (ATR)
  • ANAB 1.16
  • SEI 0.00
  • MACD
  • ANAB -0.26
  • SEI 0.00
  • Stochastic Oscillator
  • ANAB 26.97
  • SEI 0.00

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

About SEI SOLARIS ENERGY INFRASTRUCTURE INC

Solaris Energy Infrastructure Inc provides services in the oil and gas industry. Its solutions are Solaris software suite, Fluid management system, Automated control systems, Field services, Last mile management, Wet sand solutions, Power Solutions, and Integrated wellsite solution. Its segment include Solaris Power Solutions and Solaris Logistics Solutions. It derives maximum revenue from Solaris Logistics Solutions segment.

Share on Social Networks: